TNFRSF17 and Miyoshi myopathy: Lockmer et al. [30], who evaluated the antibody response after 2 doses of the BNT162b2 vaccine in 93 MM patients, have found that treatment with anti-B-cell maturation antigen (BCMA), daratumumab and dexamethasone are strongly associated with lower spike protein levels.